The Impact of Prescription Drug Reform in Ontario and its Canada-Wide Implications

Primary tabs

The Impact of Prescription Drug Reform in Ontario and its Canada-Wide Implications

Marc Kealey, President, ArcisRx.
tweet me:
Hear the future outlook for prescription drugs costs in Canada only at #COMPBEN http://bit.ly/9ynYko

Summary

TOPIC: The Impact of Prescription Drug Reform in Ontario and its Canada-Wide Implications
Plenary Session 4 at Benefits Summit 2010
WHEN: Wednesday, October 27, at 11:15 a.m
WHERE: Toronto
Priority Code: 3BL1

Featuring:
Marc Kealey, President, ArcisRx.
 
Its not often that prescription drug costs make front page news. It’s also not often that pharmacists take to the streets to demonstrate against government policy. Ontario’s recent changes to generic drug costs and fees resulted in a great deal of confusion, discussion, and anger across the industry.
 
Perhaps this is understandable when you consider that, according to the Canadian Institute for Health Information, Canada’s total drug spend is now more than $30 billion, almost 85% of which is for prescription drugs. This translates into drug costs of $14 billion for Canadian employers.
 
Marc Kealey will explain the latest changes in Ontario, the immediate implications for employers, and the future outlook for drug costs in Canada.
 
Please note that session descriptions are subject to change. To view the full agenda for this program, please click here.
 
To learn more about all of our upcoming 2010 Compensation and Benefits events in Toronto and Calgary, please click here or contact Joel Elliott at elliott@conferenceboard.ca.
 
Please quote priority code 3BL1 when registering.
Friday, October 1, 2010 - 10:00am

CONTENT: summary

Keywords: ARCISRX / BENEFITS / COMPENSATION / CONFERENCE BOARD / HR / HUMAN RESOURCES / DRUGS / PRESCRIPTION

CONTENT: summary

parse.ly